- Home
- CHRD vs PCVX Comparison
CHRD vs PCVX Comparison
Compare CHRD & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHRD | PCVX |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 7.0B |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CHRD | PCVX |
|---|---|---|
| Price | $134.46 | $58.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $149.17 | $88.25 |
| AVG Volume (30 Days) | 770.4K | ★ 945.2K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 11.14 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.56 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $84.25 | $29.87 |
| 52 Week High | $151.95 | $65.00 |
Technical Indicators
Market Signals| Indicator | CHRD | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 58.47 |
| Support Level | $129.88 | $52.18 |
| Resistance Level | $141.76 | $62.54 |
| Average True Range (ATR) | 4.66 | 2.40 |
| MACD | -0.12 | 0.38 |
| Stochastic Oscillator | 46.30 | 82.24 |
Price Performance
Historical ComparisonAbout CHRD Chord Energy Corporation
Chord Energy Corp is an independent exploration and production (E&P) company engaged in the acquisition, exploration, development and production of crude oil, NGL and natural gas prominently in the Williston Basin, with limited non-operated interests in the Marcellus Shale. It operates in one reportable business segment, which is the E&P of crude oil, NGL and natural gas. The company derives revenue from the sale of crude oil, NGL and natural gas production.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.